top biopharmaceuticals for glp-1 medication Major global pharma updates in July 2026 feature massive market movements in the obesity and segments, multi-billion dollar M&A deals, and new clinical milestones in regenerative and Top 20 biopharma kick off

Usual injectable options are slowly getting complemented by oral formulas that make administration simpler, and also improve access for more people

Amgen plans to advance AMG133 to Phase II clinical in early 2023

It has a favorable safety profile as monotherapy in patients with relapsed/refractory myeloma and also demonstrates significant single-agent activity

The emergence of GLP-1R as a popular target for weight loss is mainly attributed to its mechanistic features and the weight reduction efficacy shown by liraglutide and semaglutide

However, with reduced attention on COVID-19, sales of Comirnaty have sharply declined

Wegovy is characterized by its stronger weight loss effects, requiring only once-weekly administration